Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-AGK Polyclonal Antibody

Catalog #:   PHH89301 Specific References (44) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: Q53H12
Overview

Catalog No.

PHH89301

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human AGK (Thr15-Pro300).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

MULK,Acylglycerol kinase,mitochondrial,hAGK,Multiple substrate lipid kinase,HsMuLK,MuLK,Multi-substrate lipid kinase,AGK

Purification

Purified by antigen affinity column.

Accession

Q53H12

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • WESTERN BLOT
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with AGK antibody (PHH89301) at 1 μg/ml.

    Lane 1: Recombinant protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 58 kDa
    Observed MW: 58 kDa
References

Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors., PMID:40447351

Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2-Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy., PMID:39636206

Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies., PMID:39442037

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer., PMID:39282910

The clinical relevance of MOG antibody testing in cerebrospinal fluid., PMID:39073255

Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa., PMID:38657084

Generation and Study of Antibodies against Two Triangular Trimers Derived from Aβ., PMID:38644932

Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria., PMID:38551806

Antibodies Raised Against an Aβ Oligomer Mimic Recognize Pathological Features in Alzheimer's Disease and Associated Amyloid-Disease Brain Tissue., PMID:38292607

The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease., PMID:38290838

Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling., PMID:38036617

Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial., PMID:37414534

Locus for severity implicates CNS resilience in progression of multiple sclerosis., PMID:37380766

Mechanism of glycoform specificity and in vivo protection by an anti-afucosylated IgG nanobody., PMID:37202422

Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition., PMID:36732204

The prognostic activity of acylglycerol kinase immunohistochemical expression in colon adenocarcinoma patients., PMID:38572459

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial., PMID:36099926

A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults., PMID:35543281

Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies., PMID:35502600

Smoking and immunotherapy efficacy in lung cancer by PDL1 subgroups: An individual participant data meta-analysis of atezolizumab clinical trials: Smoking and immunotherapy efficacy in lung cancer., PMID:34862081

Novel Selection Approaches to Identify Antibodies Targeting Neoepitopes on the C5b6 Intermediate Complex to Inhibit Membrane Attack Complex Formation., PMID:34698051

COVID-19 Vaccine Response in People with Multiple Sclerosis., PMID:34687063

Immunomic Investigation of Holocyclotoxins to Produce the First Protective Anti-Venom Vaccine Against the Australian Paralysis Tick, Ixodes holocyclus., PMID:34671357

Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy., PMID:34233193

Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration., PMID:33202105

Immunogenicity of pembrolizumab in patients with advanced tumors., PMID:31395089

Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study., PMID:30510079

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies., PMID:30171081

The Legionella pneumophila Methyltransferase RomA Methylates Also Non-histone Proteins during Infection., PMID:29733858

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study., PMID:29143550

Incidence and prevalence of NMOSD in Australia and New Zealand., PMID:28550069

Augmentation of the antibody response of Atlantic salmon by oral administration of alginate-encapsulated IPNV antigens., PMID:25310804

Immunogenicity and cross protective ability of the central VP2 amino acids of infectious pancreatic necrosis virus in Atlantic salmon (Salmo salar L.)., PMID:23349841

Adsorption of the protein antigen myoglobin affects the binding of conformation-specific monoclonal antibodies., PMID:3382711

Characteristics of five monoclonal antibodies to major allergens of the short ragweed pollen., PMID:2448250

[A monoclonal antibody against ragweed pollen cross-reacting with yellow dock pollen]., PMID:4085263

Isolation and characterization of a newly identified antigen from ragweed pollen by organic solvent extraction., PMID:4064796

Antigens of Ambrosia elatior (short ragweed) pollen. III. Crossed radioimmunoelectrophoresis of ragweed-allergic patients' sera with special attention to quantification of IgE responses., PMID:6217252

Sensitivity and specificity of Czechoslovak ELISA HBsAg Sevac tests: comparison with other third-generation tests and counter-immunoelectrophoresis., PMID:6363532

The heat stability of short ragweed pollen extract and the importance of individual allergens in skin reactivity., PMID:6775022

Reactivity of ragweed allergens with IgE antibodies. Analyses by leukocyte histamine release and the radioallergosorbent test and determination of cross-reactivity., PMID:81221

[Reaction patterns of choroiditis and chorioretinitis with reference to Steffen's antiglobulin consumption test (AGC test)]., PMID:5559295

[Studies of iridocyclitis using Steffen's antiglobulin consumption test (AGC-T)]., PMID:5165663

[The anti globulin consumption test (AGC-test) in inflammatory and non inflammatory eye diseases]., PMID:5573458

Datasheet

Document Download

Anti-AGK Polyclonal Antibody.pdf

 

$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-AGK Polyclonal Antibody [PHH89301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only